Navigation Links
Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Date:9/2/2008

benefit possible from dosing alternatives", commented Per-Olof Andersson, Executive Director R&D of Almirall.

Aclidinium significantly improved the percentage of patients showing a clinically relevant improvement (greater than or equal to 4 points) in health-related quality of life compared with placebo in the ACCLAIM/COPD I study (week 52; p-value=0.025) as measured by the St. George's Respiratory Questionnaire (SGRQ). ACCLAIM/COPD II did not reach statistical significance for SGRQ at week 52 (p-value=0.074), however the study showed statistical significance at all previous time-points (p-value<0.001). Pooled analysis of both studies showed a statistically significantly higher percentage of patients improving greater than or equal to 4 units in the SGRQ at week 52 (p- value=0.04).

Secondary endpoint results demonstrated that aclidinium significantly delayed the time to the first moderate to severe exacerbation in patients with COPD in ACCLAIM/COPD II (p-value=0.01), whereas results were not significant in ACCLAIM/COPD I. In the pooled analysis of both studies, there was a positive trend in delaying the time to first moderate or severe exacerbation (p-value=0.054).

"Forest is pleased with the results of these studies and remains committed with Almirall to the development of aclidinium bromide in COPD", said Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories.

ACCLAIM/COPD study design and results

Two double-blind, multicenter, parallel-group, placebo-controlled Phase III studies were conducted, one in Europe (ACCLAIM/COPD I) and the other primarily in North America (ACCLAIM/COPD II), to evaluate the efficacy and safety of inhaled aclidinium administered once daily. A total of 1,647 patients, across 23 countries participated in these trials. Patients had a diagnosis of moderate to severe COPD and were a minimum of 40 years of age with at least a 10 pack-year smoking history. The mean FEV1 values at baseline w
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Optimer Pharmaceuticals, Inc. (Nasdaq: ... 28th Annual J.P. Morgan Healthcare Conference at the ... Wednesday, January 13, 2010. Michael N. Chang, Optimer,s ... 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time). ... audio webcast of this presentation will be accessible ...
(Date:12/16/2009)... 16 , ... Microplasmin Recruits a Total of Over,640 patients ... ThromboGenics NV (Euronext Brussels: THR), a ... of innovative treatments for eye,disease, vascular disease ... completed,the enrolment of the second Phase III ...
(Date:12/15/2009)... Inc., a global leader focused on improving blood collection, ... to provide blood centers with Alyx® system supplies needed ... filed yesterday against Fenwal by Haemonetics Corporation ( HAE). ... an advanced medical instrument used worldwide to collect two ... about 30 minutes. ,, Fenwal will ask ...
Breaking Medicine Technology:Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 2Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers 3Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 1Ethiopias climate 27 million years ago had higher rainfall warmer soil 10491 2Syphilis survey reveals need for accurate testing for early infection 59960 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 1RIT scientist shines laser light on methane in pursuit of clean fuel 10490 2
... Computerized tomographic (CT),colonography, also known as virtual colonoscopy, ... flexible tube with a camera to view the,lining ... detect cancer and,precancerous polyps and could serve as ... the results of the American College of,Radiology Imaging ...
... Biotech has become,aware of preliminary data from an ... in patients with acute ischemic stroke. In,this study, ... with,Epoetin alfa within six hours of the onset ... placebo. Ortho Biotech has reported this,information to the ...
Other Medicine Technology:Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 2Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 3Video: Large, Multi-Center Trial Demonstrates Comparable Accuracy for Virtual Colonoscopy and Standard Colonoscopy 4
(Date:12/16/2009)... through national AAD program ,, SCHAUMBURG, ... from melanoma, the deadliest form of skin cancer, ... treated, if caught early. That,s why thousands of ... screenings in their communities through the American Academy ... The program recently reached a milestone - two ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... International, Inc. (OTC Bulletin Board: MZEI) ... Board of Medizone New Zealand Ltd., a joint ... 50% interest, agreed on December 14, 2009 to ... International all global marketing rights of the company,s ... Marshall said, "Time has eroded the relevance of ...
(Date:12/16/2009)... While many of the,pharma companies are struggling ... and inmarket drugs, MarketsandMarkets on the other ... players. These pharma,forecasting solutions are designed for ... phase,III. These have a substantial impact on ... strategy, manufacturing planning, sales force,promotion, and planning. ...
(Date:12/16/2009)... could improve care, but privacy a concern, doctors ... U.S. physicians support the use of electronic medical ... two new studies show. , One study of ... in Massachusetts found that 86 percent believed electronic ... of care, 70 percent thought it would reduce ...
Breaking Medicine News(10 mins):Health News:Dermatologists Reach Skin Cancer Screening Milestone 2Health News:Dermatologists Reach Skin Cancer Screening Milestone 3Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:Medizone International, Inc. Approves Repurchase of Global Marketing Rights 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Pros and Cons of Electronic Medical Records Weighed 2
... (NEWARK, N.J., Oct. 3,2007) Rutgers College of Nursing faculty ... of the Nurse Educator of the New York Times 2007 ... three practicing nurses and one nurse educator from hundreds of ... The winners will be featured in a special section in ...
... , WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying a ... best chemotherapy for patients, U.S. research suggests. , "We ... likely to respond to standard first-line therapy and which ... second-line therapy, based on gene expression profiling," lead author ...
... The screen uses CT scans and is performed without ... new study supports the effectiveness of an innovative form ... sent through a patient,s colon. , When it ... so-called "virtual colonoscopy" is just as effective as the ...
... WEDNESDAY, Oct. 3 (HealthDay News) -- Drug-coated stents offered ... patients with blocked coronary arteries, a large Canadian study ... artery become blocked again after stent implant -- was ... getting drug-coated stents, 7.4 percent versus 10.7 percent. The ...
... WHNN radio personality,Bob Hughes, a well-known voice in the Saginaw ... is moving to Saginaw this,month. "My hearing became damaged ... the quality of my life has changed significantly since being,fitted ... Hearing,",says Hughes. "I am really enjoying my new ears." ...
... UNION CITY, Calif., Oct. 3 Abaxis, Inc.,(Nasdaq: ... point-of-care,blood chemistry analysis systems, announced today the launch ... conjunction with the Piccolo xpress(TM) point of,care analyzer. ... specifically for imaging and,radiology centers in the United ...
Other Medicine News:Health News:Rutgers College of Nursing faculty member Rachel Jones wins New York Times Nurse Award 2Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2Health News:'Virtual' Colonoscopy an Effective Option: Study 2Health News:'Virtual' Colonoscopy an Effective Option: Study 3Health News:Study Finds Benefits With Drug-Coated Stents 2Health News:Study Finds Benefits With Drug-Coated Stents 3Health News:WHNN's Bob Hughes Fitted With Hearing Aids by Mobile Care Hearing Clinic Now Serving Saginaw Area 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: